Gerald Dogon - Rosetta Genomics External Independent Director

Director

Mr. Gerald Dogon is External Independent Director of the company, since February 2007. From December 2004 to December 2006, Mr. Dogon served as a director and a member of the audit, investment and nomination committees of Scailex Corporation . From October 2005 until it was acquired by PMCSierra, Inc. in May 2006, he served as a member of the board of directors of Passave, Inc., a semiconductor company. From 1999 to 2000, he served as a director and as chairman of the audit committee of Nogatech, Inc. Mr. Dogon has also served as a member of the board of directors of Fundtech Ltd. and was a member of its audit and nominating committees. From 1994 to 1998, Mr. Dogon served as Executive Vice President and Chief Financial Officer of DSPC Inc., and in addition, from November 1997 until December 1999, as a member of its board of directors. Mr. Dogon holds a B.Comm. in Economics from the University of Cape Town. since 2007.
Age 74
Tenure 17 years
Phone972 73 222 0700
Webhttp://www.rosettagx.com
Dogon holds a B.A. in Economics from the University of Cape Town.

Rosetta Genomics Management Efficiency

The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Shunichi OgataNH Foods
N/A
James WainscottParker Hannifin
63
Garry MauroLifevantage
67
Koichi OhyamaNH Foods
N/A
Dave TooleLifevantage
59
Michael BeindorffLifevantage
63
Hajime TakamatsuNH Foods
60
Joe DavisNatural Alternatives Internatio
83
Thomas WilliamsChart Industries
59
Raymond GreerLifevantage
53
Hilda OchoaBrillembourgCementos Pacasmayo SAA
74
Iwao TakaNH Foods
62
Carl CamdenTopbuild Corp
64
Jim FischmanChart Industries
N/A
Kenya MaruyamaNH Foods
N/A
Sadakazu OgawaNH Foods
N/A
Hugo CastilloCementos Pacasmayo SAA
62
Michael PressChart Industries
68
Darwin LewisLifevantage
N/A
Gianfranco ZunigaCementos Pacasmayo SAA
N/A
Marco GarciaCementos Pacasmayo SAA
60
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in USA and traded on Nasdaq Capital Markets. It employs 86 people. Rosetta Genomics (ROSG) is traded on NASDAQ Exchange in USA and employs 86 people.

Management Performance

Rosetta Genomics Leadership Team

Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Sidransky, Independent Director
Kenneth Berlin, CEO and Pres
Anne Fields, IR Contact Officer
Joshua Rosensweig, Director
Dganit Bar, Chief Scientific Officer
Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee
Douglas Sites, Executive Vice President - Sales and Marketing
Tal YaronEldar, Independent Director
Eti Meiri, Vice President - Research
Robert Wassman, Chief Medical Officer
Oded Biran, General Counsel
Roy Davis, Director
Yitzhak Peterburg, Director
Kevin Watson, Director, Reimbursement-Managed Care
Ron Kalfus, CFO
Gerald Dogon, External Independent Director
Tali YaronEldar, External Independent Director

Rosetta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rosetta Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rosetta Genomics' short interest history, or implied volatility extrapolated from Rosetta Genomics options trading.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in Rosetta Stock

If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm